Sensei Biotherapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
FTH$12.92+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Common Stock and Stockholders’ Equity
(In thousands, except share data)
| Common Stock · Additional Paid-In · Accumulated · Accumulated Other · Total Stockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Comprehensive Income (Loss) | Equity | |
| Balance at December 31, 2022 | 30,764,160 | $3 | $302,202 | $(197,794) | $(1,004) | $103,407 |
| Stock-based compensation expense | — | — | 1,213 | — | — | 1,213 |
| Issuance of equity in exchange for compensation | 208,510 | — | 302 | — | — | 302 |
| Surrender of shares for tax withholding | (50,343) | — | (76) | — | — | (76) |
| Vesting of restricted stock shares | 49,014 | — | — | — | — | — |
| Unrealized gain on marketable securities | — | — | — | — | 181 | 181 |
| Net loss | — | — | — | (10,177) | — | (10,177) |
| Balance at March 31, 2023 | 30,971,341 | 3 | 303,641 | (207,971) | (823) | 94,850 |
| Stock-based compensation expense | — | — | 1,095 | — | — | 1,095 |
| Employee stock purchase plan expense | 25,964 | — | 31 | — | — | 31 |
| Purchase agreement, net of issuance costs and excise tax | (4,454,248) | — | (7,663) | — | — | (7,663) |
| Vesting of restricted stock shares | 40,762 | — | — | — | — | — |
| Unrealized gain on marketable securities | — | — | — | — | 274 | 274 |
| Net loss | — | — | — | (9,386) | — | (9,386) |
| Balance at June 30, 2023 | 26,583,819 | 3 | 297,104 | (217,357) | (549) | 79,201 |
| Stock-based compensation expense | — | — | 1,048 | — | — | 1,048 |
| Purchase agreement, net of issuance costs and excise tax | (1,587,302) | (1) | (2,271) | — | — | (2,272) |
| Unrealized gain on marketable securities | — | — | — | — | 147 | 147 |
| Net loss | — | — | — | (7,124) | — | (7,124) |
| Balance at September 30, 2023 | 24,996,517 | $2 | $295,881 | $(224,481) | $(402) | $71,000 |
| Balance at December 31, 2023 | 25,030,188 | $3 | $296,996 | $(231,895) | $(209) | $64,895 |
| Stock-based compensation expense | — | — | 1,216 | — | — | 1,216 |
| Issuance of equity in exchange for compensation | — | — | 293 | — | — | 293 |
| Surrender of shares for tax withholding | (12,361) | — | (10) | — | — | (10) |
| Vesting of restricted stock shares | 56,131 | — | — | — | — | — |
| Unrealized gain on marketable securities | — | — | — | — | 72 | 72 |
| Net loss | — | — | — | (7,992) | — | (7,992) |
| Balance at March 31, 2024 | 25,073,958 | 3 | 298,495 | (239,887) | (137) | 58,474 |
| Stock-based compensation expense | — | — | 795 | — | — | 795 |
| Employee stock purchase plan expense | 43,375 | — | 21 | — | — | 21 |
| Vesting of restricted stock shares | 7,000 | — | — | — | — | — |
| Unrealized gain on marketable securities | — | — | — | — | 44 | 44 |
| Net loss | — | — | — | (7,142) | — | (7,142) |
| Balance at June 30, 2024 | 25,124,333 | 3 | 299,311 | (247,029) | (93) | 52,192 |
| Stock-based compensation expense | — | — | 733 | — | — | 733 |
| Vesting of restricted stock shares | 27,046 | — | — | — | — | — |
| Unrealized gain on marketable securities | — | — | — | — | 107 | 107 |
| Net loss | — | — | — | (7,253) | — | (7,253) |
| Balance at September 30, 2024 | 25,151,379 | $3 | $300,044 | $(254,282) | $14 | $45,779 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.